瓜尔β-曼诺-寡糖化物在小鼠模型中缓解性结肠炎通过肠道微生物群调节
M Ashwini1,2, Ajit Antony1, H S Shilpa1
1Department of Microbiology and Fermentation Technology, CSIR-Central Food Technological Research Institute, Mysuru, Karnataka, India.
Journal of dietary supplements
|August 1, 2025
概括
在性结肠炎的小鼠模型中,益生菌 guar gum β-manno-oligosaccharides (GG-β-MOS) 降低了肠道炎症. 补充GG-β-MOS恢复了有益的肠道细菌和代谢物,改善了肠道健康.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其特征是肠道失调.
- 以微生物群为导向的疗法,包括益生菌补充剂,在恢复肠道健康和缓解UC症状方面表现有前途.
研究的目的:
- 在小鼠模型中研究益生菌 guar β-曼诺-寡糖化物 (GG-β-MOS) 在改善硫酸 (DSS) 诱导的性结肠炎方面的疗效.
- 评估GG-β-MOS对肠道微生物群组成,微生物群相关特征 (MAC) 和炎症标志物的影响.
主要方法:
- 成年雄性C57BL/6小鼠被给予DSS以诱导大肠炎.
- 小鼠接受了不同剂量的GG-β-MOS (500毫克/公斤和1000毫克/公斤) 的治疗.
- 评估的参数包括食物/水摄入量,疾病活动指数 (DAI),组织病理学,细胞因子水平,MAC和肠道微生物群概况.
主要成果:
- GG-β-MOS显著减轻了结肠炎症和减少了炎症蛋白质.
- 补充改善了Firmicutes/Bacteroidetes比率,并促进了诸如*Lactobacillus*和*Bifidobacteria*等益生菌的生长.
- GG-β-MOS丰富了有益细菌,与抗炎代谢物正相关,与促炎代谢物负相关.
结论:
- 在DSS诱导的性结肠炎小鼠模型中,GG-β-MOS补充剂有效地恢复了改变的肠道菌群和代谢.
- 这些变化导致了改善的粘膜修复和减少肠道炎症.
- 通过调节肠道微生物群,GG-β-MOS代表了治疗性结肠炎的潜在治疗策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
Drugs for Treatment of Diarrhea-Predominant IBS
299
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
299
Drugs for Treatment of Constipation-Predominant IBS
336
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
336
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
422
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
422
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193


